Pre-made Depatuxizumab Mafodotin benchmark antibody (Whole mAb ADC, anti-EGFR therapeutic antibody, Anti-ERBB/ERBB1/ERRP/HER1/NISBD2/PIG61/mENA Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Depatuxizumab Mafodotin benchmark antibody (Whole mAb ADC, anti-EGFR therapeutic antibody, Anti-ERBB/ERBB1/ERRP/HER1/NISBD2/PIG61/mENA Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer.[1][2] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.[3][4]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-801-1mg	1mg	4635
GMP-Bios-INN-801-10mg	10mg	Inquiry
GMP-Bios-INN-801-100mg	100mg	Inquiry
GMP-Bios-INN-801-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Depatuxizumab Mafodotin Biosimilar, Whole Mab Adc, Anti-Egfr Antibody: Anti-ERBB/ERBB1/ERRP/HER1/NISBD2/PIG61/mENA therapeutic antibody Drug Conjugate
INN Name	Depatuxizumab Mafodotin
Target	EGFR
Format	Whole mAb ADC
Derivation	Chimeric Humanized
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	AbbVie Inc. (North Chicago IL USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0